- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RadNet Subsidiary Captures Mammography AI FDA Clearance
AI-fueled mammography triage software from DeepHealth wins 510(k).
Artificial intelligence (AI) developer DeepHealth, a subsidiary of RadNet, announced Monday it has secured 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its mammography triage solution, Saige-Q.
This AI-driven screening worklist prioritization tool is DeepHealth’s first cleared product, and it automatically identifies screening exams that have suspicious findings that require additional evaluation, company officials said. By identifying these cases, the software helps radiologists streamline their workflow to be more efficient and effective.
“Saige-Q is built using our core artificial intelligence algorithms, described in a recent article in Nature Medicine,” said Bill Lotter, Ph.D., chief technology officer, and DeepHealth co-founder. “As the FDA-cleared mammography triage product that supports 3D mammography in addition to 2D mammography, Saige-Q demonstrates high performance that is maintained across different breast densities and lesion types.”
It is a tool that is designed to increase radiologist confidence in their ability to pinpoint suspicious findings, bolstering their ability to provide high-quality care.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
